GoodRx Holdings Financial Statements (GDRX)
|
|
|
|
Report date
|
|
|
12.03.2021 |
01.03.2022 |
31.12.2022 |
01.03.2023 |
29.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
550.7 |
745.4 |
766.6 |
766.6 |
750.3 |
|
790.4 |
|
Operating Income, bln rub |
|
|
-275.7 |
13.4 |
1.74 |
11.0 |
-27.0 |
|
46.0 |
|
EBITDA, bln rub |
? |
|
-257.1 |
48.0 |
65.2 |
68.5 |
108.8 |
|
146.0 |
|
Net profit, bln rub |
? |
|
-293.6 |
-25.3 |
-32.8 |
-32.8 |
-8.87 |
|
-7.92 |
|
|
OCF, bln rub |
? |
|
131.3 |
178.8 |
146.8 |
146.8 |
138.3 |
|
155.0 |
|
CAPEX, bln rub |
? |
|
35.8 |
34.5 |
55.2 |
55.2 |
55.8 |
|
87.5 |
|
FCF, bln rub |
? |
|
95.5 |
144.3 |
91.6 |
91.6 |
82.5 |
|
141.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
4.39 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-55.3% |
|
|
OPEX, bln rub |
|
|
796.8 |
685.3 |
699.7 |
699.7 |
710.3 |
|
617.9 |
|
Cost of production, bln rub |
|
|
29.6 |
46.7 |
65.1 |
65.1 |
66.9 |
|
126.4 |
|
R&D, bln rub |
|
|
61.8 |
125.9 |
143.1 |
143.1 |
135.8 |
|
123.5 |
|
Interest expenses, bln rub |
|
|
27.9 |
23.6 |
34.2 |
34.2 |
56.7 |
|
56.4 |
|
|
Assets, bln rub |
|
|
1 470 |
1 608 |
1 605 |
1 605 |
1 589 |
|
1 355 |
|
Net Assets, bln rub |
? |
|
711.4 |
831.7 |
814.8 |
814.8 |
762.0 |
|
696.4 |
|
Debt, bln rub |
|
|
704.9 |
702.3 |
65.2 |
717.0 |
711.1 |
|
57.0 |
|
Cash, bln rub |
|
|
968.7 |
941.1 |
757.2 |
757.2 |
672.3 |
|
423.8 |
|
Net debt, bln rub |
|
|
-263.8 |
-238.8 |
-691.9 |
-40.1 |
38.8 |
|
-366.8 |
|
|
Ordinary share price, rub |
|
|
40.3 |
32.7 |
4.66 |
4.66 |
6.70 |
|
5.29 |
|
Number of ordinary shares, mln |
|
|
391.7 |
400.6 |
412.9 |
412.9 |
410.3 |
|
379.7 |
|
|
Market cap, bln rub |
|
|
15 800 |
13 090 |
1 924 |
1 924 |
2 749 |
|
2 008 |
|
EV, bln rub |
? |
|
15 536 |
12 852 |
1 232 |
1 884 |
2 788 |
|
1 642 |
|
Book value, bln rub |
|
|
394 |
368 |
283 |
213 |
195 |
|
232 |
|
|
EPS, rub |
? |
|
-0.75 |
-0.06 |
-0.08 |
-0.08 |
-0.02 |
|
-0.02 |
|
FCF/share, rub |
|
|
0.24 |
0.36 |
0.22 |
0.22 |
0.20 |
|
0.37 |
|
BV/share, rub |
|
|
1.00 |
0.92 |
0.69 |
0.52 |
0.47 |
|
0.61 |
|
|
EBITDA margin, % |
? |
|
-46.7% |
6.44% |
8.50% |
8.94% |
14.5% |
|
18.5% |
|
Net margin, % |
? |
|
-53.3% |
-3.39% |
-4.28% |
-4.28% |
-1.18% |
|
-1.00% |
|
FCF yield, % |
? |
|
0.60% |
1.10% |
4.76% |
4.76% |
3.00% |
|
7.02% |
|
ROE, % |
? |
|
-41.3% |
-3.04% |
-4.03% |
-4.03% |
-1.16% |
|
-1.14% |
|
ROA, % |
? |
|
-20.0% |
-1.57% |
-2.05% |
-2.05% |
-0.56% |
|
-0.58% |
|
|
P/E |
? |
|
-53.8 |
-518.3 |
-58.6 |
-58.6 |
-310.0 |
|
-253.4 |
|
P/FCF |
|
|
165.4 |
90.7 |
21.0 |
21.0 |
33.3 |
|
14.2 |
|
P/S |
? |
|
28.7 |
17.6 |
2.51 |
2.51 |
3.66 |
|
2.54 |
|
P/BV |
? |
|
40.1 |
35.6 |
6.80 |
9.04 |
14.1 |
|
8.67 |
|
EV/EBITDA |
? |
|
-60.4 |
267.7 |
18.9 |
27.5 |
25.6 |
|
11.2 |
|
Debt/EBITDA |
|
|
1.03 |
-4.97 |
-10.6 |
-0.59 |
0.36 |
|
-2.51 |
|
|
R&D/CAPEX, % |
|
|
172.6% |
365.3% |
259.2% |
259.2% |
243.6% |
|
141.2% |
|
|
CAPEX/Revenue, % |
|
|
6.51% |
4.62% |
7.20% |
7.20% |
7.43% |
|
11.1% |
|
| GoodRx Holdings shareholders |
